Xaira Therapeutics

Challenger

AI drug discovery startup launched with $1B funding. Led by ex-Stanford president + Nobel laureate David Baker. Focus: inflammatory/immunological diseases. Founded 2024, South SF.

Updated April 2026

Company Overview

About Xaira Therapeutics

Xaira Therapeutics is an AI-powered drug discovery company launched from stealth in April 2024 with $1 billion in committed capital. Headquartered in South San Francisco, incubated by Arch Venture Partners and Foresite Capital. Led by CEO Marc Tessier-Lavigne (ex-Stanford president, ex-Genentech CSO) and co-founder David Baker (Nobel laureate, UW Institute for Protein Design).

Business Model & Competitive Advantage

Xaira builds AI models predicting biological behavior at the cellular level to design novel therapeutics, initially targeting inflammatory and immunological diseases. X-Cell, unveiled March 2026, predicts gene function from genetic perturbations. Board includes former FDA Commissioner Scott Gottlieb and Nobel laureate Carolyn Bertozzi.

Competitive Landscape 2025–2026

Investors include F-Prime, NEA, Sequoia, Lux Capital, and Lightspeed. Pre-revenue, focused on building AI platform, proprietary datasets, and advancing antibody therapy programs toward clinical development.

Revenue
$1000M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Strong Challenger

Xaira Therapeutics is an established challenger with significant market presence and competitive offerings in Healthcare & Life Sciences.

Enterprise Scale

With $1000M in revenue, Xaira Therapeutics operates at enterprise scale with proven market validation.

Frequently Asked Questions

Not So Random Others

a2z Radiology AI

Enterprise AI
Ai PoweredB2bEnterpriseHealthtechSaasStartup

a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea

Adept AI

AI Infra
Ai PoweredAutomationB2bEnterpriseInfrastructurePlatformStartupSaas

Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec

Duckie

Infrastructure
Ai PoweredAutomationB2bInfrastructurePlatformCloud NativeSaas

Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit

Plenty

AgTech & Precision Agriculture Technology
AgricultureAi PoweredHardwareIotPlatformSaasScaleupStartupB2b

Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r

Oura

Consumer Tech
B2cHardwareHealthtechIot

Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi

Nira Energy

Climate & Energy
B2bEnergy

Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify

Compare Xaira Therapeutics with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Xaira Therapeutics

Claim This Profile

Are you from Xaira Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Xaira Therapeutics Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Xaira Therapeutics vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →